CHICAGO / May 06, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY. GE HealthCare’s management team will present its growth strategies, technology portfolio, and vision for its businesses via a live webcast and will be accessible at https://investor.gehealthcare.com/news-events/events. More information, including registration details, will be available as the date draws closer.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
| Last Trade: | US$76.07 |
| Daily Change: | -0.05 -0.07 |
| Daily Volume: | 1,574,628 |
| Market Cap: | US$34.750B |
June 23, 2025 June 19, 2025 June 12, 2025 June 02, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
